Additional radiation absorbed dose estimates for Zevalin™ radioimmunotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 2, 2003, Pages 253-258

  Wiseman, Gregory A ^a   Leigh, Bryan R ^b   Dunn, William L ^a   Stabin, Michael G ^c   White, Christine A ^b  

^a MAYO CLINIC   (United States)

^b BIOGEN   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Dosimetry; Ibritumomab tiuxetan; IDEC Y2B8; Non Hodgkin's lymphoma; Radioimmunotherapy; Zevalin

Indexed keywords

IBRITUMOMAB TIUXETAN; INDIUM 111; RITUXIMAB;

CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG INFUSION; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 0038405093     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803765036436     Document Type: Conference Paper

References (15)

1. Fuks Z, Kaplan H. Recurrence rate following radiation therapy of nodular and diffuse malignant lymphomas. Radiology 1973;108:675-84.
2. Gansow O. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl Med Biol 1991;18(4):369-81.
3. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999;15:1017-25.
4. 90Y-Ibritumomab Tiuxetan Radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma. J Nucl Med 2003;44: 465-474
5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20(10):2453-63.
6. Stabin M. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37(3):538-46.
7. Siegel J, Lee R, Pawlyk D, et al. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Appl Radiat Instr 1989;16(Part B):553-9.
8. Foster D, Barrett P. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using SAAM II software system. Radiopharmaceutical Dosimetry Symposium, 1999:577-99.
9. 111In-labelled platelets in organs. Eur J Nucl Med 1982;7:80-4.
10. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40(2):37S-61S.
11. Siegel JA, Wu RK, Maurer AH. The buildup factor: effect of scatter on absolute volume determination. J Nucl Med 1985;26(4):390-4.
12. 90Y Zevalin™ (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000;27(7):766-77.
13. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99(12):4336-42.
14. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory non-Hodgkin's lymphoma. J Clin Oncol 2002;20(15):3262-9.
15. Wiseman GA, Leigh B, Erwin WD, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;94(4 Suppl):1349-57.